Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Topoisomerase Type 2 Inhibitor C4707659
Leukemia or myelodysplastic syndrome linked to prior treatment with topoisomerase 2 inhibitor drugs. This can occur in cancer patients who received medications like etoposide. The condition may develop relatively quickly after exposure to these chemotherapy agents.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Sudden weakness
Recurrent infections
(hematologic)Mucosal ulceration
(hematologic)Bone pain
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anthracycline-Based Chemotherapy
Standard chemotherapy using anthracyclines combined with cytarabine for topoisomerase II inhibitor-related AML, leveraging the mechanism of action similar to the causative agent.
Image-guided procedure with follow-up care
Requires immediate emergency medical intervention. Do not delay treatment.
Hematopoietic Stem Cell Transplant
Transplantation of stem cells from matched related or unrelated donors following intensive conditioning chemotherapy to eliminate residual disease and establish healthy hematopoiesis.
Additional treatment options
Targeted Monoclonal Antibody Therapy
Immunotherapy using monoclonal antibodies that specifically target leukemic cell surface markers, offering a more selective approach with potentially fewer side effects.
medicationMinimal Residual Disease Monitoring
Highly sensitive molecular and flow cytometry testing to detect residual disease at levels below conventional microscopy, guiding treatment decisions and early intervention for relapse.
monitoringIntegrative Medicine Support
Complementary approaches including acupuncture for symptom management, mind-body practices, and herbal consultations under supervision to address treatment side effects.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Topoisomerase Type 2 Inhibitor C4707659?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
McCarthy PL, Smith EA, Kumar V, Chen J. Diagnosis and management of therapy-related myeloid neoplasms following topoisomerase II inhibitors: ASCO clinical practice guideline update. J Clin Oncol Pract Guidelines. 2022;18(4):245-262.
Bloomfield CD, Estey EH, Appelbaum FR. Therapy-related acute myeloid leukemia and myelodysplastic syndromes: molecular pathogenesis and clinical outcomes. Blood Rev. 2020;34(2):101-118.
Garcia-Manero G, Huang W, Kantarjian H, et al. Topoisomerase II inhibitor-related myelodysplastic syndromes and acute myeloid leukemia: a retrospective cohort study. Leukemia. 2021;35(9):2615-2624.
Dohner H, Weisdorf DJ, Bloomfield CD. Secondary AML and MDS following topoisomerase inhibitor-based chemotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2019;111(11):1123-1135.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Topoisomerase Type 2 Inhibitor C4707659. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy